The systemic AAV delivery of SpCas9 components in neonatal DMD ΔEx44 mice restores dystrophin expression in nearly all skeletal and cardiac muscles, consequently preventing muscle damage and improving muscle histology and force in the treated mice [44,132,136]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.